Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

Marie Nelson; AeRang Kim; P. Mickey Williams; Sinchita Roy‐Chowdhuri; David R. Patton; Brent Coffey; Joel M. Reid; Jin Piao; Lauren Saguilig; Todd A. Alonzo; Stacey L. Berg; Nilsa C. Ramirez; Alok Jaju; Elizabeth Fox; Brenda J. Weigel; Douglas S. Hawkins; Margaret Mooney; Naoko Takebe; James V. Tricoli; Katherine A. Janeway; Nita L. Seibel; D. Williams Parsons

doi:10.1093/oncolo/oyae119

Abstract

This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, a selective oral inhibitor of BRAF V600 mutated kinase, in patients with relapsed or refractory solid tumors harboring BRAF V600 mutations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nelson et al. (2024) studied this question.

synapsesocial.com/papers/68e64b29b6db6435875dbad9 https://doi.org/10.1093/oncolo/oyae119

View Full Paper

Ask AI

Bookmark

Share

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

Abstract

Discussion

Cite This Study

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

Abstract

Discussion

Cite This Study

Keep reading

Keep reading